Find a Doctor

Find a Researcher

Stephanie Louise Gaillard, M.D., Ph.D.

Director of Gynecologic Cancer Trials
Associate Professor of Oncology

Languages: English, French

Expertise

Cervical Cancer, Chemotherapy, Endometrial Cancer, Immunotherapy, Ovarian Cancer, Targeted/Biologic Therapy ...read more

Request an Appointment

Insurance Information

Request Appointment

International Patients

+1-410-502-7683

Request Appointment

Locations

Skip Viragh Outpatient Cancer Center

Appointment Phone: 410-955-8893

201 N. Broadway
Baltimore, MD 21287 map

Background

Stéphanie Gaillard is a medical oncologist who specializes in the treatment of gynecologic malignancies. She recently joined the faculty of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and is their Director of Gynecologic Cancer Trials. Dr. Gaillard earned her medical degree and doctoral degree in cancer biology from Duke University. Following medical school, she underwent residency training in Internal Medicine and fellowship training in Medical Oncology at the Johns Hopkins School of Medicine. Dr. Gaillard’s research focuses on the development of clinical trials aimed at improving outcomes by incorporating promising new biologic, targeted, and immune therapies into standard treatment regimens. Her translational research program focuses on understanding the immune environment associated with gynecologic cancers and mechanisms of resistance to current therapies.

Titles

Director of Gynecologic Cancer Trials
Co-Director of Development Therapeutics/Phase I Clinical Trials Program
Associate Professor of Oncology
Associate Professor of Gynecology and Obstetrics

Departments / Divisions

Gynecology and Obstetrics
Oncology - Division of Women's Malignancies

Centers & Institutes

Sidney Kimmel Comprehensive Cancer Center

Education

Degrees

MD; Duke University School of Medicine (2006)

Residencies

Internal Medicine; Johns Hopkins University School of Medicine (2009)

Fellowships

Hematology and Oncology; Johns Hopkins University School of Medicine (2012)

Board Certifications

American Board of Internal Medicine (Medical Oncology) (2011)

Research & Publications

Selected Publications

View all on PubMed

Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Colombo N, Fernandez C, Alfaro V, Kahatt C, Nieto A, Zeaiter A, Aracil M, Vidal L, Pardo-Burdalo B, Papai Z, Kristeleit R, O'Malley DM, Benjamin I, Pautier P, Lorusso D. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021 Nov; 163 (2) :237-245 . doi: 10.1016/j.ygyno.2021.08.032. Epub 2021 Sep 11. PubMed PMID: 34521554

Wethington SL, Armstrong DK, Gaillard SL. Vulnerable Older Adults With Ovarian Cancer-Time to Stop Undertreating. JAMA Oncol. 2021 Jun 1; 7 (6) :831-833 . doi: 10.1001/jamaoncol.2021.0468. PubMed PMID: 33885717

Gaillard SL, Zahurak M, Sharma A, Durham JN, Reiss KA, Sartorius-Mergenthaler S, Downs M, Anders NM, Ahuja N, Rudek MA, Azad N. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. Cancer. 2019 Aug 15; 125 (16) :2837-2845 . doi: 10.1002/cncr.32138. Epub 2019 Apr 23. PubMed PMID: 31012962 ; PubMed Central PMCID: PMC6663621

Gaillard SL, Andreano KJ, Gay LM, Steiner M, Jorgensen MS, Davidson BA, Havrilesky LJ, Alvarez Secord A, Valea FA, Colon-Otero G, Zajchowski DA, Chang CY, McDonnell DP, Berchuck A, Elvin JA. Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecol Oncol. 2019 Jul; 154 (1) :199-206 . doi: 10.1016/j.ygyno.2019.04.010. Epub 2019 Apr 13. PubMed PMID: 30987772

Asaka S, Yen TT, Wang TL, Shih IM, Gaillard S. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Mod Pathol. 2019 Apr; 32 (4) :576-584. doi: 10.1038/s41379-018-0172-x. Epub 2018 Nov 6. PubMed PMID: 30401949 ; PubMed Central PMCID: PMC8201475.

PubMed

Is this you? Edit Profile